Discover how generative AI and automation are revolutionizing neuroscience drug discovery by enabling scalable, high-throughput human iPSC neuronal models with unprecedented efficiency and translatability, reducing the reliance on less relevant cell lines.
In this webinar, you will learn:
A key challenge in neuroscience drug discovery and development is access to disease-relevant patient brain tissue. It is not possible to routinely study human brain tissue to find or optimize therapeutic candidates.
The advent of induced pluripotent stem cells (iPSCs) has provided the potential to fundamentally change this by offering a non-invasive and renewable source of human neurons.
But complex iPSC-derived neuronal models are traditionally challenging to integrate with drug discovery programs because of their inherent complexity, limiting reproducibility, throughput, and turnaround times.
Our team has been working to scale and standardize iPSC neuronal models for drug discovery.
We have built an automated cell culture platform named the Neuron Factory. It utilizes automation, brightfield microscopy, and generative AI to enable high-throughput screening and medicinal chemistry for neuroscience research.
Join us in this webinar to see how this platform has fundamentally changed our drug discovery flow charts by emphasizing neuronal models early on, limiting the need to use less relevant cell lines.
Enabling the routine study of human neuronal models will ultimately increase the translatability of neuroscience research.
Robert Ihry
Senior Principal Scientist
Novartis Institute for Biomedical Research
Watch Now